“Di­ag­nos­tics is still mas­sively un­der-val­ued and un­der-uti­lized”

BioSpectrum (Asia) - - Bio Content -

With heart dis­ease, obe­sity and di­a­betes rates on the rise, chronic dis­ease is set to con­tinue its up­ward trend. Ac­cord­ing to the World Health Or­ga­ni­za­tion, chronic ill­ness glob­ally is ex­pected to rise by 57 per cent by 2020, with al­most half of to­tal chronic dis­ease deaths at­trib­uted to car­dio­vas­cu­lar diseases. Ef­fec­tive man­age­ment of pa­tients with chronic diseases re­quires con­stant and reg­u­lar mon­i­tor­ing, of­ten us­ing home mon­i­tor­ing de­vices. As a re­sult, se­cu­rity and pri­vacy of real-time data from th­ese de­vices to health­care pro­fes­sion­als be­comes ques­tion­able. Roche Di­ag­nos­tics looks to join the col­lab­o­ra­tion formed be­tween In­fo­com­mu­ni­ca­tions Me­dia De­vel­op­ment Author­ity of Sin­ga­pore (IMDA), DEX and PwC Sin­ga­pore, with the aim to plug this gap us­ing Ocean Pro­to­col, a blockchain-based tech­nol­ogy that al­lows se­cure, trans­par­ent and trace­able ex­change of data. Lance Lit­tle, Manag­ing Direc­tor, Re­gion Asia Pa­cific, Roche Di­ag­nos­tics re­cently spoke to BioSpec­trum Asia about this part­ner­ship, ef­fec­tive use of med­i­cal data, key op­por­tu­ni­ties in di­ag­nos­tics space and com­pany’s plans in the com­ing years. Edited ex­cerpts;

Can you tell us more about the part­ner­ship you have en­tered with IMDA, PWC and DEX? How will pa­tients be ben­e­fited from this part­ner­ship?

As part of our planned col­lab­o­ra­tion with DEX, IMDA and PwC Sin­ga­pore, Roche Di­ag­nos­tics is ini­ti­at­ing a pi­lot study to de­ter­mine how de­cen­tral­ized blockchain data ex­change tech­nol­ogy – Ocean Pro­to­col – can en­able trusted and se­cure real-time data shar­ing from our CoaguChek pa­tient de­vice to the hos­pi­tal in­for­ma­tion sys­tem can help to im­prove the cur­rent prac­tice and stan­dards of care for pa­tients on blood- thin­ning ther­apy.

For th­ese pa­tients, reg­u­lar test­ing of the In­ter­na­tional Nor­malised Ra­tio (INR) lev­els is nec­es­sary to en­sure the right dosage and mon­i­tor the ef­fec­tive­ness of their ther­apy. Poor con­trol may lead to com­pli­ca­tions such as bleed­ing or stroke.

With our Blue­tooth-en­abled Roche CoaguChek home mon­i­tor­ing de­vice, pa­tients un­der ther­apy can con­ve­niently test and mon­i­tor their INR lev­els, in less than five min­utes. Reg­u­lar test­ing of INR will in­di­cate if pa­tients are at risk of com­pli­ca­tions or whether they are safe and within ther­a­peu­tic range. In the past, re­sults would typ­i­cally would be avail­able for the doc­tor to re­view dur­ing pa­tient con­sul­ta­tions, which on av­er­age are once ev­ery six months. How­ever, with au­to­matic real-time ac­cess to re­sults, doc­tors can bet­ter man­age their pa­tients on co­ag­u­la­tion mon­i­tor­ing ver­sus the cur­rent stan­dard of care. Most data ex­changes cur­rently op­er­ate un­der cen­tral­ized model where a copy of data is ex­changed un­der the rules and gov­er­nance of the in­di­vid­ual en­vi­ron­ment. Un­der this model, there is limited prove­nance, au­ditabil­ity, and trust. In ad­di­tion, data own­ers can lose con­trol of their data as­sets and more im­por­tantly, pri­vacy and se­cu­rity can be eas­ily com­pro­mised.

The Ocean Pro­to­col can present a unique so­lu­tion for ad­dress­ing to­day’s data ex­change chal­lenge by com­bin­ing blockchain tech­nol­ogy and a trust frame­work that is co-de­vel­oped with IMDA to en­sure safe, se­cure, and trusted data ex­change.

So, with this pi­lot project we are de­ter­min­ing the safe and se­cure shar­ing of the INR re­sults of pa­tients on anti-co­ag­u­la­tion ther­apy from the home mon­i­tor­ing de­vice to the hos­pi­tal in­for­ma­tion sys­tem.

Ul­ti­mately, through the pi­lot, we hope to gain a bet­ter un­der­stand­ing of ex­ist­ing need-gaps, which could en­able us to cre­ate a data-driven health­care en­vi­ron­ment that pro­vides physi­cians with the right dig­i­tal tools to sup­port de­ci­sion mak­ing, and en­sure bet­ter pa­tient care.

Which diseases/ con­di­tions does Roche Di­ag­nos­tics in­tend to fo­cus its ef­forts on in near fu­ture?

Roche Di­ag­nos­tics of­fers the in­dus­try’s broad­est range of in vitro di­ag­nos­tics (IVD) so­lu­tions. We bring in­no­va­tions that are rel­e­vant and can meet the needs of the lo­cal pop­u­la­tions.

Our prod­uct port­fo­lio ranges from blood glu­cose me­ters for peo­ple with di­a­betes and point-of-care test­ing de­vices for use in doc­tors’ of­fices, to high­through­put anal­y­sers for hos­pi­tals and com­mer­cial di­ag­nos­tic lab­o­ra­to­ries. We also sup­ply state-of-theart in­stru­ments and reagents for life sci­ence re­search.

Sim­ply put, we will con­tinue to fo­cus our ef­forts on lever­ag­ing sci­en­tific knowl­edge and bring­ing in­no­va­tive so­lu­tions that can ad­dress un­met med­i­cal needs. Take for ex­am­ple our HPV test. Around the globe, there has been a re­duc­tion of women dy­ing from cer­vi­cal can­cer be­cause of the in­tro­duc­tion of pap smears. How­ever, re­search has shown that this test can miss in­stances of cer­vi­cal can­cer. The hu­man pa­pil­loma virus (HPV) is the lead­ing cause of cer­vi­cal can­cer, caus­ing more than 99 per cent of cases ac­cord­ing to the World Health Or­gan­i­sa­tion (WHO).

Roche de­vel­oped a new tech­nol­ogy which iden­ti­fies the 14 most preva­lent high-risk HPV geno­types, and can pro­vide spe­cific geno­typ­ing in­for­ma­tion for HPV types 16 and 18 which cause 70 per cent of all cer­vi­cal can­cers. With the in­tro­duc­tion of the HPV test, high risk pa­tients can be iden­ti­fied, mean­ing pre­ven­ta­tive mea­sures can be put in place with­out de­lay, ul­ti­mately sav­ing more women’s lives.

Most re­cently, Aus­tralia phased out the pap smear test in favour of the HPV test so that women are tested for the pres­ence of the HPV rather than test­ing for ab­nor­mal cells, which may not oc­cur un­til many years af­ter ini­tial in­fec­tion with HPV.

How do you en­vi­sion Roche Di­ag­nos­tics de­vel­op­ing in the next 20 years from now?

We’re at an in­ter­est­ing point in time. The health­care in­dus­try is evolv­ing so quickly that it’s dif­fi­cult to pre­dict the changes in the next decade, much less en­vi­sion where we’ll be in 20 years. But I will say that as the global leader in in vitro di­ag­nos­tics, I am con­fi­dent that Roche Di­ag­nos­tics will con­tinue to de­liver the best pos­si­ble di­ag­nos­tic so­lu­tions to im­prove peo­ple’s lives. As the in­dus­try leader, we have the op­por­tu­nity to en­hance health­care de­liv­ery and ul­ti­mately ben­e­fit so­ci­ety as a whole.

Whilst di­ag­nos­tics has al­ways been one of the pil­lars of health­care, it is now po­si­tioned to play a key role in rev­o­lu­tion­is­ing health­care. Dig­i­tal has al­ready emerged as a key driver in the health­care space, but what we will see more of in the com­ing decades is the ap­pli­ca­tion of dig­i­tal and tech tools in the di­ag­nos­tics en­vi­ron­ment, and the ad­vent of dig­i­tal di­ag­nos­tics.

So­phis­ti­cated dig­i­tal di­ag­nos­tic tools will em­power doc­tors to make the right de­ci­sions, al­low pa­tients to have more con­trol over their health and well-be­ing, and give pay­ers and pol­i­cy­mak­ers the con­fi­dence that they are in­vest­ing in the right so­lu­tions.

Di­ag­nos­tics is still mas­sively un­der-val­ued and un­der-uti­lized. To­day, it rep­re­sents just 2- 3 per cent of all health­care spend­ing but in­flu­ences 60 -70 per cent of med­i­cal de­ci­sion mak­ing. In times to come, I hope we can change this. It is when we col­lec­tively har­ness the true po­ten­tial of di­ag­nos­tics that we can en­hance the over­all stan­dard of care.

Priyanka Bajpai priyanka.bajpai@mmac­tiv.com

Lance Lit­tle,Manag­ing Direc­tor, Re­gion Asia Pa­cific, Roche Di­ag­nos­tics

Lance Lit­tle, Manag­ing Direc­tor, Re­gion Asia Pa­cific, Roche Di­ag­nos­tics

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.